Eli Lilly and Company’s (LLY) donanemab is not recommended for marketing authorization for the treatment of early symptomatic Alzheimer’s disease, according to an opinion released by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). Lilly will ask CHMP to re-examine. Europeans living with early symptomatic […]
Alzheimer’s
Eliminating amyloid from the brain may prevent symptoms in those who are destined to acquire early-onset Alzheimer’s disease, according to a clinical experiment. This suggests the need for additional research.
Using a novel animal model of Alzheimer’s disease, the study raises the possibility of a breakthrough in therapeutic approaches.
The active ingredient in the diabetes and weight-loss medications Wegovy and Ozempic is semaglutide, a glucagon-like peptide receptor (GLP-1R) molecule that reduces appetite and aids in blood sugar regulation in type 2 diabetes.
The report states that vascular dementia is the second most frequent subtype of dementia after Alzheimer’s disease. Still, the two illnesses are different clinically.
This new research, published in Alzheimer’s & Dementia, suggested that the cognitive impairments of COVID-19 presented similar fundamental changes within the brain to those showing evidence of dementia.
The researchers collected several thousand cells in each brain from a region of the brain that is affected by Alzheimer’s and ageing.
New findings out of Emory University are shaking theories of the origin of Alzheimer’s the leading cause of dementia among older adults worldwide.
Methylation of mRNA impairs the brain’s energy supply by interfering with the synthesis of ND5, a subunit of complex I of the respiratory chain.
Numerous immune system genes are among the altered genes that increase a person’s chance of developing Alzheimer’s disease
